Clinical tools and biomarkers to predict preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Research

Background:

• Preeclampsia is a major global cause of maternal and perinatal mortality.
• Existing predictive tests, like first-trimester screening, have limited utility, particularly for term preeclampsia.
• Current biomarkers (sFlt-1, placental growth factor) offer good exclusion but modest sensitivity.

Purpose of the Study:

• To highlight the clinical need for effective preeclampsia prediction tests.
• To review existing diagnostic and screening options for preeclampsia.
• To summarize current research on novel biomarkers for improved preeclampsia prediction.

Main Methods:

• Literature review of preeclampsia screening and biomarker research.
• Analysis of the clinical utility of current predictive algorithms and biomarkers.
• Synthesis of findings from studies investigating novel biomarkers.

Main Results:

• Limited options exist for effective preeclampsia prediction, especially for term disease.
• First-trimester screening is effective for preterm preeclampsia but not term disease.
• Novel biomarkers are being investigated from various organs implicated in preeclampsia pathogenesis.

Conclusions:

• An effective predictive test for preeclampsia is clinically imperative.
• Existing biomarkers have limitations in sensitivity for widespread prediction.
• Ongoing research focuses on identifying novel biomarkers to improve early diagnosis and management.